Tango Therapeutics Inc., incorporated in Delaware on May 21, 2020, is a biotechnology company dedicated to discovering new drug targets and delivering next-generation precision medicine for the treatment of cancer. Tango uses a patient-starting and endpoint approach to discover and develop therapies for key cancer targets using the genetic principle of synthetic lethality. This includes expanding the scope of precise oncology targets into new areas, such as tumor suppressor gene loss and its contribution to the ability of cancer cells to evade immune cell killing. 

TNGX

TNGX Profile